VOORHEES, N.J., March 4 Currently, no definitive standard of care exists for adolescent and young adults (AYA) with acute lymphoblastic leukemia (ALL). Recent research suggests that AYAs treated with pediatric treatment protocols have better outcomes than those treated with adult treatment protocols. It is important that healthcare professionals working with this unique patient population understand and apply evidence-based treatment strategies for ALL in order to maximize patient outcomes.
Advertisement
To address the need for current education on ALL in adolescents and young adults, Robert Michael Educational Institute LLC (RMEI) and Postgraduate Institute for Medicine (PIM) are jointly sponsoring a complimentary continuing education virtual lecture titled Acute Lymphoblastic Leukemia in Adolescents and Young Adults: Strategies for Improved Patient Care. This activity, which is supported by an educational grant from Enzon Pharmaceuticals, is certified for physicians, nurses and pharmacists.
Advertisement
Lewis B. Silverman, MD, from the Dana-Farber Cancer Institute, Children's Hospital Boston and Harvard Medical School in Boston, Massachusetts, serves as faculty for this virtual lecture.
Healthcare professionals can visit http://cme.medscape.com/viewprogram/30652 to access this free continuing education activity.
RMEI is a medical education company that specializes in independent, continuing medical education designed for clinicians to improve and deliver quality medical care to patients. The goal of RMEI educational offerings is to promote continuous professional development and the improvement of health outcomes. RMEI works closely with medical experts to develop activities that improve diagnosis and treatment leading to better outcomes for patients. These activities include national and international symposia, teleconferences, live meetings, enduring print materials and interactive Internet programs.
For other educational opportunities, please visit www.RMEI.com.
SOURCE Robert Michael Educational Institute LLC
